LINSIGRA Trademark

Trademark Overview


On Thursday, June 24, 2021, a trademark application was filed for LINSIGRA with the United States Patent and Trademark Office. The USPTO has given the LINSIGRA trademark a serial number of 90793302. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 15, 2024. This trademark is owned by Allakos Inc.. The LINSIGRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and therapeutic preparations for the treatment of gastrointestinal, skin, multi-organ, respiratory, ophthalmic, autoimmune, cardiovascular, central nervous system, endocrine, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, urogenital, urological, and viral diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic esophagitis, ulcerative colitis, crohn's disease, irritable bowel syndrome, functional gastrointestinal disease, chronic urticaria, atopic dermatitis, indolent systemic mastocytosis, mast cell activation syndrome, idiopathic pulmonary fibrosis, eosinophilic asthma, asthma, conjunctivitis, vitiligo, and viral infections
linsigra

General Information


Serial Number90793302
Word MarkLINSIGRA
Filing DateThursday, June 24, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 19, 2022

Trademark Statements


Goods and ServicesPharmaceutical and therapeutic preparations for the treatment of gastrointestinal, skin, multi-organ, respiratory, ophthalmic, autoimmune, cardiovascular, central nervous system, endocrine, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, urogenital, urological, and viral diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic esophagitis, ulcerative colitis, crohn's disease, irritable bowel syndrome, functional gastrointestinal disease, chronic urticaria, atopic dermatitis, indolent systemic mastocytosis, mast cell activation syndrome, idiopathic pulmonary fibrosis, eosinophilic asthma, asthma, conjunctivitis, vitiligo, and viral infections

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllakos Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Carlos, CA 94070

Party NameAllakos Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Carlos, CA 94070

Trademark Events


Event DateEvent Description
Monday, June 28, 2021NEW APPLICATION ENTERED
Wednesday, September 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 15, 2022ASSIGNED TO EXAMINER
Wednesday, March 16, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 16, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, March 16, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 16, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, March 16, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 29, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 29, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 29, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 30, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 14, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 13, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, December 13, 2022SOU EXTENSION 1 FILED
Tuesday, December 13, 2022SOU EXTENSION 1 GRANTED
Thursday, December 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 8, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 8, 2023SOU EXTENSION 2 FILED
Thursday, June 8, 2023SOU EXTENSION 2 GRANTED
Saturday, June 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 22, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 22, 2023SOU EXTENSION 3 FILED
Monday, July 15, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, July 15, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Friday, November 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED